Linezolid-resistant enterococci: report of the first isolates in the United Kingdom

被引：123

作者：

Auckland, C ^{[1
]}

Teare, L

Cooke, F

Kaufmann, ME

Warner, M

Jones, G

Bamford, K

Ayles, H

Johnson, AP

机构：

[1] Southampton Gen Hosp, Southampton Publ Hlth Lab, Southampton SO16 6YD, Hants, England

[2] Chelmsford Publ Hlth Lab, Chelmsford, Essex, England

[3] Hammersmith Hosp, Dept Microbiol, London, England

[4] Cent Publ Hlth Lab, Lab Hosp Infect, London NW9 5HT, England

[5] Cent Publ Hlth Lab, Antibiot Resostance Monitoring & Reference Lab, London NW9 5HT, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2002年 / 50卷 / 05期

关键词：

linezolid; resistance; enterococci;

D O I：

10.1093/jac/dkf246

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Linezolid, the first oxazolidinone antibacterial agent to be developed for clinical use, was licensed in the UK in early 2001. We report the first three examples of resistant enterococci (two isolates of Enterococcus faecium and one Enterococcus faecalis) isolated in the UK, which were obtained from patients who had received linezolid. The linezolid MICs for the resistant isolates were 64 mg/L. Pulsed-field gel electrophoresis (PFGE) analysis of the linezolid-susceptible and -resistant isolates from two of the patients, combined with sequence analysis of rRNA, indicated that resistance developed in previously susceptible strains, most probably via a point mutation in the 23S rRNA.

引用

页码：743 / 746

页数：4

共 10 条

[1]

CHIMA C, 2002, P SOC HEALTHC EP AM

[2] Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid [J].

Gonzales, RD ;

Schreckenberger, PC ;

Graham, MB ;

Kelkar, S ;

DenBesten, K ;

Quinn, JP .

LANCET, 2001, 357 (9263) :1179-1179

[3] Nosocomial spread of linezolid-resistant, vancomycin-resistant enterococcus faecium [J].

Herrero, IA ;

Issa, NC ;

Patel, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (11) :867-869

[4] Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone:: Report from the SENTRY Antimicrobial Surveillance Program [J].

Jones, RN ;

Della-Latta, P ;

Lee, LV ;

Biedenbach, DJ .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 42 (02) :137-139

[5] Control of a nosocomial outbreak of vancomycin resistant Enterococcus faecium in a paediatric oncology unit:: risk factors for colonisation [J].

Nourse, C ;

Murphy, H ;

Byrne, C ;

O'Meara, A ;

Breatnach, F ;

Kaufmann, M ;

Clarke, A ;

Butler, K .

EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (01) :20-27

[6] Resistance to linezolid: Characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci [J].

Prystowsky, J ;

Siddiqui, F ;

Chosay, J ;

Shinabarger, DL ;

Millichap, J ;

Peterson, LR ;

Noskin, GA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :2154-2156

[7] The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria [J].

Swaney, SM ;

Aoki, H ;

Ganoza, MC ;

Shinabarger, DL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (12) :3251-3255

[8] Linezolid resistance in a clinical isolate of Staphylococcus aureus [J].

Tsiodras, S ;

Gold, HS ;

Sakoulas, G ;

Eliopoulos, GM ;

Wennersten, C ;

Venkataraman, L ;

Moellering, RC ;

Ferraro, MJ .

LANCET, 2001, 358 (9277) :207-208

[9]

WOODFORD N, 2002, IN PRESS J CLIN MICR

[10]

ZURENKO G, 1999, P 39 ANN INT C ANT A, P117

← 1 →